형광 가이드 수술 시스템 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Fluorescence Guided Surgery Systems Market reached a valuation of USD 101.3 million in 2023 and is projected to grow at a CAGR of 14.1% from 2024 to 2032. FGS systems enhance surgical procedures by providing real-time imaging that differentiates tissues with fluorescent dyes, supporting more precise and effective surgeries.

Government initiatives focused on enhancing surgical infrastructure are driving significant demand for fluorescence-guided surgery (FGS) systems. These initiatives typically involve investments in advanced medical technologies, facility upgrades, and encouraging the use of innovative tools that improve surgical precision and outcomes. The grant supports OnLume's development of its FGS system, aiming to refine the device for improved intraoperative visualization of blood vessels and small lymphatic tissues, ultimately enhancing surgical accuracy and patient results.

The market is categorized by type into VS3 Iridium systems, SPY systems, PDE systems, and others. In 2023, the SPY system segment led with a market share of 38.1% and is expected to grow at a 15% CAGR. Known for its advanced imaging and precision, the SPY system uses ICG fluorescence imaging to visualize blood flow and tissue perfusion essential for enhancing surgical accuracy by enabling surgeons to assess tissue viability and make informed decisions in real-time.

In terms of application, the market is divided into laparoscopic/endoscopic surgery and open surgery. Open surgery held the largest share in 2023 at 54.2%, largely due to its role in complex, extensive procedures. FGS systems are particularly beneficial in open surgeries, where they enable detailed visualization of tumors and adjacent tissues, facilitating precise removal of malignant cells and minimizing the risk of residual disease.

The U.S. dominated the North American FGS market, generating USD 38.4 million in revenue in 2023. As a hub for medical technology innovation, the U.S. leads in growth of FGS systems with advanced imaging and new fluorescent agents. The high prevalence of cancer further drives demand for FGS, as surgeons prioritize techniques that enhance outcomes in challenging surgeries.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Growth in targeted surgeries for cancer and cardiovascular disorders
    • 3.2.1.3 Growing focus towards improving surgical outcomes and reducing operating time
    • 3.2.1.4 Government initiatives aimed at improving surgical infrastructure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of surgical equipment and consumables
    • 3.2.2.2 Limited reimbursement coverage for fluorescence imaging procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 SPY system
• 5.3 Photo Dynamic Eye (PDE) system
• 5.4 VS3 iridium system
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Surgery, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Open surgery
• 6.3 Laparoscopic/endoscopic surgery

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer surgeries
• 7.3 Cardiovascular surgeries
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgery centers
• 8.4 Oncology centers
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 B. Braun
• 10.2 Carl Zeiss
• 10.3 Danaher Corporation
• 10.4 Getinge
• 10.5 Hamamatsu Photonics
• 10.6 Intuitive Surgical
• 10.7 KARL STORZ
• 10.8 Medtronic
• 10.9 Olympus Corporation
• 10.10 OnLume
• 10.11 Shimadzu Corporation
• 10.12 Stryker Corporation
• 10.13 Samvardhana Motherson International
• 10.14 Sumitomo Mitsui Financial Group